Type 1 Diabetes TrialNet Clinical Network Hub

1 型糖尿病 TrialNet 临床网络中心

• 批准号: 9899045
• 负责人: CARLA J GREENBAUM
• 金额: $ 100万
• 依托单位: BENAROYA RESEARCH INST AT VIRGINIA MASON
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-31 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9899045
• 关键词: Antibodies; Area; Australia; Autoantibodies; Canada; Chairperson; Clinical; Clinical Trials; Clinical Trials Network; Communication; Conduct Clinical Trials; Data; Development; Diabetes Mellitus; Disease; Disease Progression; Enrollment; Finland; Germany; Goals; Grant; Individual; Information Dissemination; Insulin-Dependent Diabetes Mellitus; International; Italy; Leadership; Mission; Monitor; Natural History; Participant; Phase I Clinical Trials; Prevention; Process; Research Institute; Research Personnel; Risk; Site; Sweden; Thinking; Time; United States National Institutes of Health; clinical Diagnosis; design; innovation; insulin dependent diabetes mellitus onset; member; prevent; recruit; screening; success

PROJECT SUMMARY / ABSTRACT TrialNet's mission is to bring disease modifying therapy to clinical use in type 1 diabetes (T1D) with a primary focus on conducting clinical trials at early stages of disease to prevent or delay clinical onset. TrialNet is an international consortium of twenty-five Clinical Centers and hundreds of Affiliate sites in US, Canada, UK, Sweden, Finland, Germany, Italy, and Australia. These sites together with the TrialNet Coordinating Center (TNCC), the TrialNet Clinical Hub (HUB), and members of our Collaborative Mechanistic Studies Panel (CMSP), (a) conduct natural history studies to describe the progression of T1D and identify individuals for clinical trials, (b) conduct clinical trials of disease modifying therapy both prior to and after clinical diagnosis, and (c) increase the scientific value of trials through mechanistic studies involving investigators within and external to TrialNet. The mission of the Type 1 Diabetes TrialNet Hub is to increase the efficiency of critical Network activities by supporting collaborative and innovative approaches for screening, recruitment, retention, trial development and implementation, and dissemination of results. With considerable success during the previous grant period, this application describes our proposal to continue to serve as the Diabetes TrialNet Clinical HUB. We focus on three areas; activities to (a) enhance risk screening to identify at-risk individuals, (b) enhance enrollment and retention in clinical trials, and (c) enhance clinical administration to effectively implement TrialNet's goals.

项目总结/摘要 TrialNet的使命是将疾病修饰疗法用于1型糖尿病（T1 D）的临床应用， 重点在疾病的早期阶段进行临床试验，以预防或延迟临床发作。TrialNet是一个 由25个临床中心和数百个美国、加拿大、英国 瑞典、芬兰、德国、意大利和澳大利亚。这些网站连同TrialNet协调中心 （TNCC），TrialNet临床中心（HUB）和我们的合作机制研究小组（CMSP）的成员， (a)进行自然史研究，以描述T1 D的进展，并确定临床试验的个体， (b)在临床诊断之前和之后进行疾病改善疗法的临床试验，以及（c）增加 通过涉及TrialNet内部和外部调查人员的机制研究，提高试验的科学价值。 1型糖尿病试验网络中心的使命是通过以下方式提高关键网络活动的效率 支持筛选、招募、保留、试验开发和 实施和传播结果。 在上一个赠款期间取得了相当大的成功，本申请描述了我们继续 作为糖尿病试验网临床中心。我们集中在三个方面：（a）加强风险筛查 识别高危个体，（B）提高临床试验的入组率和保留率，以及（c）提高临床 以有效实现TrialNet的目标。